Pharmaceutical drug
Identifiers |
---|
CAS Number | |
---|
ChemSpider | |
---|
UNII | |
---|
KEGG | |
---|
Chemical and physical data |
---|
Formula | C6504H10028N1744O2018S46 |
---|
Molar mass | 146416.72 g·mol−1 |
Lifastuzumab vedotin (INN;[1] development code DNIB0600A) is an experimental monoclonal antibody-drug conjugate designed for the treatment of cancer.[2]
This drug was developed by Genentech/Roche.
References
- ^ World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110" (PDF). WHO Drug Information. 27 (4).
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Lifastuzumab Vedotin, American Medical Association.